Tuesday, September 21, 2010

IDBI BANK = UPDATE DT 21.09.2010 = GOOD QTRLY PERFORMANCE = CAPITAL INFUSION BY GOI = FUTURE BRIGHT


IDBI Bank Limited
NSE Symbol   IDBI
UPDATE DT 21.09.2010
IDBI Bank's Q1 2011 net up 46% to Rs.251 Crore
 
Highlights of Q1 FY 11 financial results vis-à-vis Q1 FY 10 (June 30, 2009) = Details from the bank’s press releases
  • Net profit up 46 % to Rs.251 Crore (from Rs.172 Crore)
  • Fee based income grew by 53% to Rs.385 Crore (from Rs.252 Crore)
  • NII grew by 171% to Rs.851 Crore (from Rs.315 Crore)
  • NIM at 1.64% (from 0.81% )
  • Business up 37% to Rs.2,92,533 Crore (from Rs.2,13,526 Crore)
  • Deposits increased by 36% to Rs.1,57,204 Crore (from Rs.1,15,554 Crore)
  • Advances up by 38% to Rs.1,35,329 Crore (from Rs.97,972 Crore)
  • Total assets grew by 29% to Rs.2,24,657 Crore (from Rs.1,74,608 Crore)
Mumbai, July 22, 2010:
Working results:    
(Rs. Crore)


Q1 2010-11
Q1 2009-10
FY 2009-10

Total Income
4755
4219
17564

Interest income
4289
3461
15261

Non-Interest Income
466
758
2302

Total Expenses
3924
3463
14837

Interest expenses
3438
3147
13005

Operating expenses
486
316
1831

Operating Profit
831
756
2727

Provisions (net)
580
584
1696

Net Profit
251
172
1031



Profitability:
IDBI reported a net profit of Rs 251 crore for the quarter ended June 30, 2010 as against Rs.172 crore in the corresponding quarter. This amounts to an increase in net profit by 46% for the quarter compared to corresponding period last year.
Net Interest Income (NII) for the quarter ended June 30, 2010 stood at Rs 851 crore as against Rs.315 crore in the corresponding quarter of the previous year, recording a growth of 171%.
Fee based income during the quarter has shown considerable improvement to Rs.385 Crore as against Rs.252 Crore in the previous quarter, recording a growth of 53%.

Business:
As of June 30, 2010, IDBI’s total business (deposits and advances) stood at Rs.292533 crore as against Rs. 213526 crore as of June 30, 2009, registering a growth of 37%.
Deposits increased to Rs.157204 Crore at end-June 2010 from Rs. 115554 crore at end-June 2009, with a robust growth of 36%.
Advances also increased by 38% to Rs.135329 crore, as compared to Rs. 97972 crore as at end- June 2009.
As of June 30, 2010, aggregate assets stood at Rs.224657 crore as against Rs. 174608 crore as on June 30, 2009, registering a growth of 29%.
CAR:
The Bank's CAR stood at 11.86% (Tier-I 6.69%) as of June 30, 2010.

Significant Developments from April 2010 till date
  • Shri R.M. Malla took over as Chairman & Managing Director of IDBI Bank Ltd w.e.f. July 9, 2010. Prior to taking up his current assignment, Shri Malla was Chairman & Managing Director of Small Industries Development Bank of India (SIDBI).
  • IDBI Bank Ltd. switched over to the Base Rate system from the existing Benchmark Prime Lending Rate (BPLR) system w.e.f. 01.07.2010. The Bank has decided to fix its Base Rate at 8% p.a.
  • IDBI Bank Ltd. was awarded the coveted international certification ISO 9001:2008 for all its Currency Chests across the country in June 2010.
  • IDBI Bank Ltd. opened its first overseas branch at The Dubai International Financial Centre (DIFC). Hon'ble Union Minister of State for Finance, Shri Namo Narain Meena, in the presence of Shri B. P. Singh, Deputy Managing Director, IDBI Bank Ltd, inaugurated the branch on June 2, 2010.
  • Government of India has communicated its intention to infuse Rs. 3119.04 crores as equity capital on preferential basis. The Bank has initiated necessary steps to complete the Statutory/ Regulatory formalities for this purpose.

RESULTS IN FIGURES:
IDBI BANK
30-Jun-10
31-Mar-10
DIF%1
30-Jun-09
DIF%2
Interest on Advances
315282
292049
7.96
260101
21.22
Income on Investments
113455
114549
-0.96
85367
32.9
Income on Balances With RBI
73
-7
-1142.9
572
-87.24
Others
88
1548
-94.32
290
-69.66
Interest Earned
428898
408139
5.09
346330
23.84
Other Income
46618
54706
-14.78
75561
-38.3
Total Income
475516
462845
2.74
421891
12.71
Interest Expended
343780
332121
3.51
314686
9.25
Employees Cost
23357
28554
-18.2
11932
95.75
Other Operating Expenses
25263
32774
-22.92
19658
28.51
Operating Expenses
48620
61328
-20.72
31590
53.91
Operating Profit
83116
69396
19.77
75615
9.92
Provisions
50177
54247
-7.5
56032
-10.45
Profit before tax
32939
15149
117.43
19583
68.2
Tax Expense
7850
-16692
-147.03
2400
227.08
Net Profit After Tax
25089
31841
-21.21
17183
46.01
Net Profit
25089
31841
-21.21
17183
46.01
Face Value
10
10
0
10
0
Paid-up Equity
72489
72486
0
72478
0.02
Dividend (%)
-
30

-

Shares Held by GOI(%)
52.67
52.67
0
52.67
0
Capital Adequacy Ratio
11.86
11.31
4.86
12.3
-3.58
Basic EPS before Extraordinary items
3.46
4.39
-21.18
2.37
45.99
 % of Gross/Net NPA
1.19
1.02
16.67
1.23
-3.25

ANNOUNCEMENTS
TO THE NSE

09-09-2010        Idbi Bank Limited has informed the Exchange that "The Board of Directors of IDBI Bank Ltd., at their meeting held on September 9, 2010, have given in-principle approval to the proposal for merger of IDBI Gilts Ltd. (a 100% unlisted subsidiary of IDBI Bank Ltd.) with IDBI Bank Ltd". 
27-07-2010        Idbi Bank Limited has informed the Exchange regarding a press release dated July 26, 2010, titled "IDBI Bank Receives Rs.3119.04 crore from the GOI towards Preferential Issue of Equity Shares".
23-07-2010        Idbi Bank Limited has informed the Exchange that : "In terms of the Special Resolution under Sections 81(1A), 31, 94 and 97 of the Companies Act, 1956 passed at the 6th AGM of the Bank, held on July 22, 2010, the Board of Directors of the Bank has approved Preferential issue of 259509110 equity shares of Rs.10/- each at a price of Rs.120.19 per share (comprising of Rs.10/- face value and Rs.110.19 share premium amount) aggregating to Rs.3119.04 crore to Govt. of India at its meeting held on July 22, 2010".
22-07-2010        Idbi Bank Limited has informed the Exchange that the Board of Directors of IDBI Bank Ltd., at their meeting held on July 22, 2010, have given in-principle approval to the proposal for merger of IDBI Homefinance Ltd. (a 100% unlisted subsidiary of IDBI Bank Ltd.) with IDBI Bank Ltd.
22-07-2010        IDBI Bank Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2010 as follows: Interest earned of Rs. 428898 lacs for the quarter ending on 30-JUN-2010 against Rs. 346330 lacs for the quarter ending on 30-JUN-2009. Interest expended of Rs. 343780 lacs for the quarter ending on 30-JUN-2010 against Rs. 314686 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. 25089 lacs for the quarter ending on 30-JUN-2010 against Rs. 17183 lacs for the quarter ending on 30-JUN-2009.
11-06-2010        Idbi Bank Limited has informed the Exchange that "By passing a Resolution by Circulation, Board of Directors of the Bank has approved a proposal for increase in the Authorised Share Capital of the Bank from Rs. 1250 Crore to Rs.2000 Crore (divided into 200 Crore equity shares of Rs.10/- each) as well as for empowering the Board to raise capital aggregating to not more than Rs.700 crore (Stock exchanges will be notified in advance as per listing agreement provisions when the Board of the Bank takes specific decision to raise capital and the mode of raising capital in future under the enabling shareholders' resolution) subject to passing Special Resolution at the ensuing Annual General Meeting of the Bank under Sections 31,94,97 and 81(1A) of the Companies Act, 1956 and relevant provisions of other applicable laws, regulations and guidelines, if any".
30-04-2010        Idbi Bank Limited has informed the Exchange that the Board of Directors of the Bank at its meeting held on April 30, 2010, dividend at Rs.3 per share on equity shares has been recommended by the Board for adoption by the Shareholders.   
30-04-2010        IDBI Bank Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAR-2010 as follows: Interest earned of Rs. 408139 lacs for the quarter ending on 31-MAR-2010 against Rs. 326221 lacs for the quarter ending on 31-MAR-2009. Interest expended of Rs. 332121 lacs for the quarter ending on 31-MAR-2010 against Rs. 278081 lacs for the quarter ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 31841 lacs for the quarter ending on 31-MAR-2010 against Rs. 31367 lacs for the quarter ending on 31-MAR-2009.
30-04-2010        IDBI Bank Limited has informed the Exchange regarding the standalone Results for the year ended on 31-MAR-2010 as follows: Interest earned of Rs. 1527263 lacs for the year ending on 31-MAR-2010 against Rs. 1163162 lacs for the year ending on 31-MAR-2009. Interest expended of Rs. 1300522 lacs for the year ending on 31-MAR-2010 against Rs. 1030572 lacs for the year ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 103113 lacs for the year ending on 31-MAR-2010 against Rs. 85853 lacs for the year ending on 31-MAR-2009.

SUMMARY :
IDBI BANK  is on a good growth Path. Recently it has paid Advance tax of Rs 182 Cr vs Rs 62 Cr in corresponding period of last year. Its current Market price is Rs.142.
Considering its medium to long term prospects, it appears to be a good bet for Investors for investors with a medium to long term horizon
 *  *  *    E N D  *  *  *

VENUS REMEDIES = UPDATE DT 21.09.2010 = WORLDWIDE PATENTS = BRIGHT FUTURE = GOOD PROFITABILITY


Venus Remedies Limited
NSE Symbol   VENUSREM
UPDATE DT 21 09 2010
Q1 FY 2011 REVIEW
Net Sales at Rs.82.17 Cr is higher by 1.71% compared to previous Qtr (Rs.80.78 Cr) and higher by 5.88% compared to corresponding Qtr of FY10 (Rs.77.60 Cr)
Raw Materials cost at Rs.42.27 Cr is down by 8.69% from previous Qtr (Rs.46.29 Cr) and down by 8.54% compared to corresponding Qtr (Rs.46.21 Cr).
Net Profit is Rs.10.93 Cr – down by 14.31% from previous Qtr (Rs.12.75CR) – and also down by 0.99% from corresponding Qtr (Rs.11.04 Cr). This, as we see, is basically due to higher depreciation and lower other Income.
Basic EPS is Rs.12.87 against a Face Value of Rs.10. Previous Qtr EPS was Rs.15.05 and corresponding Qtr of FY10 EPS was Rs.13.03.
As can be seen from the announcements of Venus Remedies to NSE and other news in Media, the company is getting periodical patents in all continents for its products. Hence, Future Profitability is likely to be a steep upward curve.
At the current rate of EPS, current annual EPS is likely to be  around Rs.55.
At the current Market price of Rs.315, the PE Ratio comes to just 5.73 – which seems to indicate huge scope for price appreciation.

RESULTS  IN  FIGURES :

Quarter Ended
30-Jun-10
31-Mar-10
Dif%1
30-Jun-09
Dif%2
Net Sales
8216.7
8078.37
1.71
7760.15
5.88
SIT & WIP
443
-103.79
-526.82
-120.7
-467.03
Raw Materials
4226.6
4628.71
-8.69
4621.17
-8.54
Employees Cost
419.8
399.42
5.1
367.16
14.34
Depreciation
197.1
58.64
236.12
195.25
0.95
Other Exp
1230.6
1297.21
-5.13
1152.36
6.79
Total Expen
6517.1
6280.19
3.77
6215.24
4.86
Profit from Operations
1699.6
1798.18
-5.48
1544.91
10.01
Other Income
1.5
38.01
-96.05
2.8
-46.43
Profit B I&EI
1701.1
1836.19
-7.36
1547.71
9.91
Interest
336.3
299.71
12.21
217.99
54.27
Profit A I BB EI
1364.8
1536.48
-11.17
1329.72
2.64
Profit before tax
1364.8
1536.48
-11.17
1329.72
2.64
Tax expense
272
261.12
4.17
225.99
20.36
Net Profit after tax
1092.8
1275.36
-14.31
1103.73
-0.99
Net Profit
1092.8
1275.36
-14.31
1103.73
-0.99
Face Value (In Rs
10
10
0
10
0
Paid Up Equity Share Capital
849.2
847.31
0.22
847.31
0.22
Basic EPS A EI
12.87
15.05
-14.49
13.03
-1.23
Diluted EPS A EI
-
-

13.03

Basic EPS B EI
12.87
15.05
-14.49
13.03
-1.23
Diluted EPS B EI
-
-

13.03

Public holding (%)
74.65
74.59
0.08
74.59
0.08

ANNOUNCEMENTS
TO THE NSE
14-09-2010    Venus Remedies Limited has informed the Exchange that "Venus Remedies Research Blockbuster "Sulbactomax" Gets European Union Patent"
24-08-2010    Venus Remedies Limited has informed the Exchange that the Board of Directors in its Meeting held on August 24, 2010 has inter alia approved issue of Fully Convertible warrants on a preferential basis to Sunev Pharma Solutions Ltd. a promoter group company upto 5% of the total capital in accordance with SEBI ( Substantial Acquisitions and Takeovers) Regulations, 1997. The same is also subject to applicable provisions of SEBI/Companies Act and approval of shareholders at the forthcoming Annual General Meeting.
05-08-2010    Venus Remedies Limited has informed the Exchange vide its letter dated August 05, 2010, regarding "Grant of another Market Authorization for its carbapenem injection in Portugal to German arm of Venus Remedies Limited".
31-07-2010    Venus Remedies Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on July 31, 2010, recommended a dividend @ of 30% i.e. Rs. 3/- per share for the financial year ended March 31, 2010 subject to approval of the same by shareholders at the Annual General Meeting.
20-07-2010    Venus Remedies Limited has informed the Exchange vide its letter dated July 20, 2010 that "Venus Remedies gets GMP accreditation from Sudan for its seven super specialty injectable manufacturing facilities".
28-06-2010    Venus Remedies Limited has informed the Exchange vide its letter dated June 28, 2010, regarding "Venus Remedies enters Australasia region with grant of patent for Potentox from New Zealand".
15-06-2010    Venus Remedies Limited has informed the Exchange vide its letter dated June 15, 2010 regarding "US based Lockheed Martin Foundation, Texas University to assist Venus Remedies to market Ampucare a miraculous wound healing product of the Company in US."   
10-06-2010    Venus Remedies Limited has informed the Exchange that the Company and the bondholders had arrived at a Settlement Agreement dated March 3, 2010 with the FCCB holders for settlement of FCCBs of USD 12m. The Settlement was arrived at USD 14m (including interest component) against a cash payment of USD 9m and rollover of USD 5m of FCCBs for a period of 5 years, until February 15, 2015. In accordance with the said Agreement, the Company has made full and final payment of USD 9m and also received approval of Reserve Bank of India for rollover of FCCBs of USD 5m. With this, the entire issue of FCCB has been fully and finally settled with the FCCB holders.
22-05-2010    Venus Remedies Limited has informed the Exchange that the Company has received approval from the Reserve Bank of India for rollover of FCCB USD 5mn with YTM @ 4% with maturity till February 15, 2015.
18-05-2010    Venus Remedies Limited has informed the Exchange vide its letter dated May 17, 2010 regarding "Venus Remedies to launch the world's first once-a-day pain killer injection. Aceclofenac OD gets patent from Indian patent office".
03-05-2010    Venus Remedies Limited has informed the Exchange vide its letter dated May 03, 2010 that "Venus Remedies ties up with IMTECH and Panjab Univ to develop Typhoid detection kits".
24-04-2010    Venus Remedies Limited has informed the Exchange regarding the outcome of Board Meeting held on April 24, 2010.
09-04-2010    Venus Remedies Limited has informed the Exchange vide its letter dated April 09, 2010 tha " Venus Remedies receives GMP Certification from Botswana

NEWS IN THE MEDIA
16.09.2010 : Venus Remedies has obtained the European Union patent for its researched anti-infection product “Sulbactomax”. The patent granted by European Patent organisation (EPO) will cover the entire European Union including the United Kingdom, France, Germany, Italy, Spain, and Switzerland.
14.09.2010 : Venus Remedies has received European Union patent for its researched anti-infection product 'Sulbactomax'. According to a company announcement, the patent granted by European Patent Organisation (EPO) covers the entire EU region.
20.07.2010 : Venus Remedies today said that seven units at its Baddi plant in Himachal Pradesh have received the Good Manufacturing Practices (GMP) accreditation from Sudan's National Medicine and Poison Board.
28.07.2010: Venus Remedies Ltd,  has marked its presence in Australasia by receiving a patent from Commissioner of Patents , Trademarks & Design, Intellectual Property office of  New Zealand for its antibiotic Potentox, a fixed dose combination of cefepime and amikacin.  This unique combination of a cephalosporin with aminoglycoside is a super specialty product indicated for the treatment of Hospital acquired pneumonia, community acquired pneumonia and Febrile Neutropenia.
28.06.2010: Venus Remedies today said that it has received patent for its anti-pneumonia drug in New Zealand and hopes to generate handsome revenues there following the grant.
18.05.2010: The company, which claimed that the drug is the world's first once-in-a-day injectable painkiller, aims a 10 per cent market share in the segment with this product.
04.05.2010 : Venus Remedies Ltd has tied up with the Institute of Microbial Technology (Imtech), a renowned research centre of the Council of Scientific and Industrial Research (CSIR), and Department of Microbiology, Panjab University, to jointly develop a diagnostic kit for typhoid.
18.03.2010: Drug maker Venus Remedies is planning to foray into the European drug market with its innovative generic injectables and cancer drugs.
12.11.2009 : Venus Remedies has bagged patent for Potentox drug from South African patent controller. This is the company’s third product patent in South Africa this year. Companies Intellectual Property Registration Office, South Africa, has granted the company patent of two more drugs – Sulbactomax and Tobracef.
23.09.2010: Drug firm Venus Remedies today said it has signed an out-licensing deal with a Korean firm for selling Sulbactomax drug, used in the treatment of pre or post-surgical infection and also for respiratory infections, in South Korea.
01.09.2009: Drug manufacturer Venus Remedies today said its research product 'Mebatic', useful in treatment of waterborne diseases, has got sales and manufacturing approvals from the Drugs Controller General of India (DCGI).
06.05.2009 :Venus Remedies’ stock surged 10.5 per cent to close the day at Rs 188.65 on getting nod from the Drugs Controller General of India’s (DCGI) for a cancer drug.
*  *  *    E N D   *  *  *